Generic placeholder image

当代阿耳茨海默病研究

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Research Article

用于治疗神经退行性疾病的4-氨基吡啶肽衍生物的合成和生物学研究

卷 20, 期 2, 2023

发表于: 06 June, 2023

页: [120 - 129] 页: 10

弟呕挨: 10.2174/1567205020666230602142012

价格: $65

摘要

背景:阿尔茨海默病(AD)和多发性硬化症(MS)导致神经退行性过程,对全世界数百万人产生负面影响。他们的治疗仍然很困难,而且实际上是不完整的。治疗这些神经退行性疾病最常用的药物之一是4-氨基吡啶。但由于其毒性大,限制了其使用。 目的:本工作的目的是获得与4-氨基吡啶相比毒性更低的新的4-氨基吡啶肽衍生物。 方法:采用连续缩合法在溶液中进行合成。用熔点、核磁共振和质谱对新衍生物进行了表征。使用ACD/Percepta v.2020.2.0软件在计算机上研究了重要的ADME(吸收、分布、代谢和排泄)特性。根据标准方案测定小鼠急性毒性。所有新衍生物通过标准的mtt比色法在体外对人(HEP-G2, BV-173)和小鼠(NEURO 2A)肿瘤细胞系进行细胞毒活性测试。采用荧光法测定β-分泌酶抑制活性。 结果:得到了含有β-分泌酶抑制肽(Boc-Val-Asn-Leu-Ala-OH)类似物的4-氨基吡啶衍生物。试验化合物的体内毒性高达1500毫克/公斤。对不同来源肿瘤细胞系的细胞毒性筛选显示,所有研究的4-氨基吡啶类似物的生长抑制作用可以忽略不计。 结论:报道了新的4-氨基吡啶肽衍生物的合成。急性毒性研究表明,与4-氨基吡啶相比,新化合物的毒性低约150倍,这可能归因于它们的肽片段。

关键词: 4-氨基吡啶,阿尔茨海默病,多发性硬化症,毒性,细胞毒性,神经递质。

[1]
a) Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci 1991; 12(10): 383-8.
[http://dx.doi.org/10.1016/0165-6147(91)90609-V] [PMID: 1763432];
b) Mudher A, Lovestone S. Alzheimer’s disease-do tauists and baptists finally shake hands? Trends Neurosci 2002; 25(1): 22-6.
[http://dx.doi.org/10.1016/S0166-2236(00)02031-2] [PMID: 11801334]
[2]
a) St George-Hyslop PH. Genetic factors in the genesis of Alzheimer’s disease. Ann N Y Acad Sci 2000; 924(1): 1-7.
[http://dx.doi.org/10.1111/j.1749-6632.2000.tb05552.x] [PMID: 11193785];
b) Moncsor M. Diagnosis and treatment of Alzheimer’s disease. Curr Med Chem 2005; 5(1): 5-13.
[3]
Vassar R. BACE1: The beta-secretase enzyme in Alzheimer’s disease. J Mol Neurosci 2004; 23(1-2): 105-14.
[http://dx.doi.org/10.1385/JMN:23:1-2:105] [PMID: 15126696]
[4]
Ivanov I, Danalev DL, Vezenkov LT. New peptide mimetics with potential β-secretase inhibition activity. Izv Him 2009; 41(2): 143-8.
[5]
a) Ivanov I, Vezenkov L, Danalev D. New peptide analogues of beta-secretase inhibitor OM 99-2, modified in P3-position. Collect Czech Chem Commun 2009; 11: 47-50.;
b) Ivanov I, Danalev D, Vezenkov L. Design and synthesis of new peptide mimetics with potential β-secretase inhibition activity. The Proceedings of the 30-th European Peptide Symposium; 2008 Aug 31 – Sep 5; Helsinki, Finland. 240-1.
[6]
Chaudhuri A. Multiple sclerosis is primarily a neurodegenerative disease. J Neural Transm (Vienna) 2013; 120(10): 1463-6.
[http://dx.doi.org/10.1007/s00702-013-1080-3] [PMID: 23982272]
[7]
Raine CS. Multiple sclerosis: Immune system molecule expression in the central nervous system. J Neuropathol Exp Neurol 1994; 53(4): 328-37.
[http://dx.doi.org/10.1097/00005072-199407000-00002] [PMID: 8021705]
[8]
Prineas J, McDonald W. Demyelinating diseases. In: Graham D, Lantos P, Eds Greenfield’s neuropathology. New York: Oxford University Press 1997; pp. 813-96.
[9]
Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359(9313): 1221-31.
[http://dx.doi.org/10.1016/S0140-6736(02)08220-X] [PMID: 11955556]
[10]
Weinstock-Guttman B, Ramanathan M, Zivadinov R. Interferon-beta treatment for relapsing multiple sclerosis. Expert Opin Biol Ther 2008; 8(9): 1435-47.
[http://dx.doi.org/10.1517/14712598.8.9.1435] [PMID: 18694361]
[11]
Arnon R. The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: Personal reflections. Immunol Lett 1996; 50(1-2): 1-15.
[http://dx.doi.org/10.1016/0165-2478(96)02506-0] [PMID: 8793553]
[12]
Savin Z, Lejbkowicz I, Glass-Marmor L, Lavi I, Rosenblum S, Miller A. Effect of Fampridine-PR (prolonged released 4-aminopyridine) on the manual functions of patients with Multiple Sclerosis. J Neurol Sci 2016; 360: 102-9.
[http://dx.doi.org/10.1016/j.jns.2015.11.035] [PMID: 26723984]
[13]
Li Y, Hai S, Zhou Y, Dong BR. Cholinesterase inhibitors for rarer dementias associated with neurological conditions. Cochrane Database Syst Rev 2015; 3(3): CD009444.
[http://dx.doi.org/10.1002/14651858.CD009444.pub3] [PMID: 25734590]
[14]
Fampyra, INN-Fampridine. Summary of product characteristics, EMA. 2017. Available from: https://www.ema.europa.eu/en/documents/variation-report/fampyra-h-c-2097-ii-0036-g-epar-assessment-report-variation_en.pdf
[15]
Schafer EW Jr, Brunton RB, Cunningham DJ. A summary of the acute toxicity of 4-aminopyridine to birds and mammals. Toxicol Appl Pharmacol 1973; 26(4): 532-8.
[http://dx.doi.org/10.1016/0041-008X(73)90291-3] [PMID: 4771602]
[16]
Kostadinova I, Landzhov B, Danchev N, Vezenkov L, Oskar A. Effect of 4-aminopyridine and newly synthesised original 4-aminopyridine derivativeson on cuprizone-induced demyelination of corpus callosum in mice. Compt Rend Acad Bulg Sci 2020; 73(8): 1139-44.
[17]
Kostadinova I, Danchev N, Nikolova I, Vezenkov L. Ivanov Tch. Effects of 4-aminopyridine derivatives with a peptide molety on scopolamine-induced memory impairment in mice. Pharmacia 2017; 64(3): 22-30.
[18]
Vezenkov L, Anchev B, Fidanov K, Tsekova DS, Kostadinova I. New 4-Aminopyridine derivatives containing peptide fragment designed for the treatment of Alzheimer disease and multiple sclerosis, Peptides. Proceedings of the 35-th European Peptide Symposium 35th European Peptide Symposium. 2018 Aug 26-31; Ireland Dublin City University. 2018; pp. 241-3.
[19]
López-García J, Lehocký M. Humpolíček P, Sáha P. HaCaT Keratinocytes response on antimicrobial atelocollagen substrates: Extent of cytotoxicity, cell viability and proliferation. J Funct Biomater 2014; 5(2): 43-57.
[http://dx.doi.org/10.3390/jfb5020043] [PMID: 24956439]
[20]
Vezenkov LT, Tsekova DS, Kostadinova I, Mihaylova R, Vassilev NG, Danchev ND. Synthesis of new galanthamine-peptide derivatives designed for prevention and treatment of Alzheimer’s disease. Curr Alzheimer Res 2019; 16(3): 183-92.
[http://dx.doi.org/10.2174/1567205016666190228123923] [PMID: 30819081]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy